vs
Side-by-side financial comparison of Cue Biopharma, Inc. (CUE) and Local Bounti Corporation (LOCL). Click either name above to swap in a different company.
Cue Biopharma, Inc. is the larger business by last-quarter revenue ($21.9M vs $12.5M, roughly 1.8× Local Bounti Corporation). Cue Biopharma, Inc. runs the higher net margin — 7.2% vs -69.8%, a 77.0% gap on every dollar of revenue. On growth, Cue Biopharma, Inc. posted the faster year-over-year revenue change (1292.3% vs 23.7%). Over the past eight quarters, Cue Biopharma, Inc.'s revenue compounded faster (257.5% CAGR vs 21.9%).
Cue Biopharma is a clinical-stage biotechnology company focused on developing novel targeted immunotherapies for cancer, autoimmune disorders, and inflammatory diseases. Its proprietary platform enables precise T-cell activity modulation, with core operations in North America and global pharma partnerships to advance lead product candidates through clinical trials.
Local Bounti Corporation is a U.S.-based sustainable indoor agriculture firm growing fresh, pesticide-free leafy greens, herbs and produce via advanced hydroponic and vertical farming tech. It serves North American retail and food service partners, focusing on low environmental impact and stable year-round supply.
CUE vs LOCL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.9M | $12.5M |
| Net Profit | $1.6M | $-8.7M |
| Gross Margin | — | 12.2% |
| Operating Margin | 9.0% | -106.1% |
| Net Margin | 7.2% | -69.8% |
| Revenue YoY | 1292.3% | 23.7% |
| Net Profit YoY | 116.7% | 76.0% |
| EPS (diluted) | $0.05 | $1.52 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $21.9M | $12.5M | ||
| Q3 25 | $2.1M | $12.2M | ||
| Q2 25 | $3.0M | $12.1M | ||
| Q1 25 | $421.0K | $11.6M | ||
| Q4 24 | $1.6M | $10.1M | ||
| Q3 24 | $3.3M | $10.2M | ||
| Q2 24 | $2.7M | $9.4M | ||
| Q1 24 | $1.7M | $8.4M |
| Q4 25 | $1.6M | $-8.7M | ||
| Q3 25 | $-7.4M | $-26.4M | ||
| Q2 25 | $-8.5M | $-21.6M | ||
| Q1 25 | $-12.3M | $-37.7M | ||
| Q4 24 | — | $-36.3M | ||
| Q3 24 | $-8.7M | $-34.3M | ||
| Q2 24 | $-10.2M | $-25.3M | ||
| Q1 24 | $-12.3M | $-24.1M |
| Q4 25 | — | 12.2% | ||
| Q3 25 | — | 11.5% | ||
| Q2 25 | — | 12.2% | ||
| Q1 25 | — | 12.6% | ||
| Q4 24 | — | 5.4% | ||
| Q3 24 | — | 13.8% | ||
| Q2 24 | — | 14.3% | ||
| Q1 24 | — | 9.4% |
| Q4 25 | 9.0% | -106.1% | ||
| Q3 25 | -353.4% | -149.4% | ||
| Q2 25 | -292.3% | -127.7% | ||
| Q1 25 | -2921.4% | -135.6% | ||
| Q4 24 | — | -166.6% | ||
| Q3 24 | -264.2% | -176.0% | ||
| Q2 24 | -390.6% | -146.8% | ||
| Q1 24 | -737.8% | -122.9% |
| Q4 25 | 7.2% | -69.8% | ||
| Q3 25 | -346.6% | -216.6% | ||
| Q2 25 | -287.1% | -178.3% | ||
| Q1 25 | -2911.4% | -324.6% | ||
| Q4 24 | — | -360.1% | ||
| Q3 24 | -259.6% | -335.2% | ||
| Q2 24 | -382.7% | -267.6% | ||
| Q1 24 | -719.1% | -286.9% |
| Q4 25 | $0.05 | $1.52 | ||
| Q3 25 | $-0.07 | $-1.18 | ||
| Q2 25 | $-0.09 | $-1.63 | ||
| Q1 25 | $-0.17 | $-4.32 | ||
| Q4 24 | — | $-4.24 | ||
| Q3 24 | $-0.17 | $-4.01 | ||
| Q2 24 | $-0.20 | $-3.00 | ||
| Q1 24 | $-0.25 | $-2.89 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.1M | $4.2M |
| Total DebtLower is stronger | — | $483.1M |
| Stockholders' EquityBook value | $26.4M | $-166.2M |
| Total Assets | $42.2M | $410.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.1M | $4.2M | ||
| Q3 25 | $11.7M | $6.2M | ||
| Q2 25 | $27.5M | $5.3M | ||
| Q1 25 | $13.1M | $18.0M | ||
| Q4 24 | $22.5M | $937.0K | ||
| Q3 24 | $32.4M | $317.0K | ||
| Q2 24 | $30.0M | $9.7M | ||
| Q1 24 | $41.0M | $8.2M |
| Q4 25 | — | $483.1M | ||
| Q3 25 | — | $484.9M | ||
| Q2 25 | — | $478.3M | ||
| Q1 25 | — | $480.0M | ||
| Q4 24 | — | $436.8M | ||
| Q3 24 | $1.0M | $398.4M | ||
| Q2 24 | $2.0M | $374.0M | ||
| Q1 24 | $3.0M | $329.8M |
| Q4 25 | $26.4M | $-166.2M | ||
| Q3 25 | $13.2M | $-158.1M | ||
| Q2 25 | $18.2M | $-132.7M | ||
| Q1 25 | $6.6M | $-134.5M | ||
| Q4 24 | $17.5M | $-100.5M | ||
| Q3 24 | $25.4M | $-65.6M | ||
| Q2 24 | $21.6M | $-32.8M | ||
| Q1 24 | $30.0M | $-9.4M |
| Q4 25 | $42.2M | $410.5M | ||
| Q3 25 | $31.6M | $417.8M | ||
| Q2 25 | $40.7M | $426.8M | ||
| Q1 25 | $22.3M | $447.2M | ||
| Q4 24 | $32.2M | $428.0M | ||
| Q3 24 | $44.8M | $430.8M | ||
| Q2 24 | $42.3M | $438.1M | ||
| Q1 24 | $54.0M | $413.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.04× | — | ||
| Q2 24 | 0.09× | — | ||
| Q1 24 | 0.10× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.1M | $-3.1M |
| Free Cash FlowOCF − Capex | — | $-3.6M |
| FCF MarginFCF / Revenue | — | -29.1% |
| Capex IntensityCapex / Revenue | 0.0% | 3.9% |
| Cash ConversionOCF / Net Profit | -0.68× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-42.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.1M | $-3.1M | ||
| Q3 25 | $-9.0M | $-8.9M | ||
| Q2 25 | $-3.4M | $-8.7M | ||
| Q1 25 | $-8.2M | $-9.6M | ||
| Q4 24 | $-36.3M | $1.2M | ||
| Q3 24 | $-7.5M | $-17.2M | ||
| Q2 24 | $-10.0M | $-4.0M | ||
| Q1 24 | $-9.8M | $-7.1M |
| Q4 25 | — | $-3.6M | ||
| Q3 25 | — | $-10.1M | ||
| Q2 25 | $-3.4M | $-14.6M | ||
| Q1 25 | $-8.3M | $-14.5M | ||
| Q4 24 | $-36.4M | $-8.6M | ||
| Q3 24 | $-7.5M | $-30.0M | ||
| Q2 24 | $-10.0M | $-28.8M | ||
| Q1 24 | $-9.8M | $-42.1M |
| Q4 25 | — | -29.1% | ||
| Q3 25 | — | -82.8% | ||
| Q2 25 | -116.5% | -121.0% | ||
| Q1 25 | -1976.7% | -125.1% | ||
| Q4 24 | -2309.3% | -85.3% | ||
| Q3 24 | -225.7% | -293.1% | ||
| Q2 24 | -376.2% | -305.4% | ||
| Q1 24 | -573.0% | -501.8% |
| Q4 25 | 0.0% | 3.9% | ||
| Q3 25 | 0.0% | 9.7% | ||
| Q2 25 | 0.9% | 48.9% | ||
| Q1 25 | 35.6% | 42.8% | ||
| Q4 24 | 4.2% | 97.6% | ||
| Q3 24 | 0.0% | 125.0% | ||
| Q2 24 | 0.4% | 263.0% | ||
| Q1 24 | 3.2% | 417.3% |
| Q4 25 | -0.68× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CUE
| Immuno Scape Collaboration And License Agreement | $9.5M | 43% |
| BI Collaboration And License Agreement | $8.1M | 37% |
| Other | $4.3M | 20% |
LOCL
Segment breakdown not available.
